For the Quarter Ending September 2022
In the first half of the third quarter of 2022, Clofazimine's price trends significantly increased and gained momentum. Significant energy materials' rising costs on the upstream price front have put enough pressure on Clofazimine's market prices. Furthermore, a sluggish increase in production levels has been caused by increased costs and persistent material constraints. In addition, the uptick in upstream pricing and gloomy market sentiments despite a limited supply of raw materials and delivery delays were associated with the decrease in demand. As a result, both local and foreign market orders somewhat increased. However, Clofazimine costs in the North American market steadied at the end of the third quarter.
The third quarter of 2022 has seen a considerable market rise in Clofazimine pricing. Business operations across nations have been significantly damaged by the recurrence of COVID cases in China. The product's domestic market shipment and transportation have been affected due to restricted port mobility. As a result, domestic producers have updated their prices to preserve the balance between supply and demand. Additionally, in the third half of Q3, the regular order from the downstream pharmaceutical companies worsened the traders' perceptions of the Clofazimine market. Additionally, the growing demand from the global market, which has values estimated at INR 45005000/MT with an average quarterly inclination of 2.33%, has contributed to Clofazimine's positive market expansion.
In the European region, Clofazimine pricing patterns have fluctuated. Due to the strong demand from downstream pharmaceutical companies, Clofazimine spot offers have sharply increased. Significant energy materials are scarce due to supply chain bottlenecks caused by Russia's invasion of Ukraine. Excessive energy costs and a lack of raw materials have hampered pharmaceutical companies' growth and put significant pressure on stock prices. The merchants were cautious about including the growing energy costs in their Clofazimine offerings. Furthermore, According to the observed market environment, the impact of Russia's invasion of Ukraine and the associated geopolitical uncertainties stayed contained and narrowed the gap between imports and exports near the end of the quarter.
For the Quarter Ending June 2022
The price trends of Clofazimine have gained an upward momentum and significantly surged in the first half of the second quarter of 2022. On the upstream price front, the price of significant energy materials has escalated, provoking enough cost pressure on the market values of Clofazimine. Furthermore, the rising costs and sustained material shortage have contributed to an obtuse rise in production levels. In addition, the slowdown in demand was linked to the propelled upstream prices and bearish market sentiments amid constrained raw material supplies and delivery delays. As a result, The order from domestic and international markets rose fractionally. However, towards the end of the second quarter, the prices of Clofazimine stabilized in the North-American region.
During the second quarter of 2022, Clofazimine prices have demonstrated weak market growth. The resurgence of COVID cases in China has severely impacted business activities across the nations. The constrained port movement has resulted in stockpiling of the product in the domestic market. Thus, domestic manufacturers have revised their quotations to maintain the equilibrium between supply and demand. Furthermore, in the second half of Q2, the subdued demand from the downstream pharmaceuticals firms deteriorated the market sentiments of Clofazimine among the traders. In addition, the limited inquiries from the international market have supported Clofazimine's negative market growth with values accessed at INR 42000090/MT with a quarterly declination of 1.54%.
The price trends of Clofazimine have oscillated in the European region. The spot offers of Clofazimine have witnessed a steep rise, owing to the robust demand from downstream pharmaceutical firms. The supply chain bottlenecks brought on by Russia's invasion of Ukraine have resulted in the limited availability of significant energy materials. The exorbitant energy prices and shortages of raw materials have impacted the progress of pharmaceutical firms and substantially pressured the stockholder's quotations. The traders were cautious about passing on the rising energy costs in the offers for Clofazimine. Furthermore. as per the observed market scenario, towards the quarter end, the imports fell more sharply than export as the impact of Russia's invasion of Ukraine and the related geopolitical uncertainty remained contained and narrowed the market sentiments.